Related Experiment Videos
Chemotherapy of oligodendroglial tumours: current developments
1partment of Neuro-Oncology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Forum (Genoa, Italy)
|July 6, 2000
Summary
Oligodendrogliomas (ODG) are a type of glioma with a better prognosis. Genetic markers, specifically 1p36 and 19q13.3 deletions, predict chemotherapy response in ODG patients.
Area of Science:
- Neuro-oncology
- Cancer Genetics
- Clinical Trials
Background:
- Oligodendroglioma (ODG) is a glioma subtype with a generally better prognosis than astrocytic tumors.
- Diagnostic challenges exist in differentiating ODG from astrocytoma, leading to inter-observer variability.
- Genetic hallmarks of ODG include 1p36 and 19q13.3 chromosomal deletions.
Purpose of the Study:
- To review the clinical and genetic characteristics of oligodendroglioma.
- To evaluate the efficacy of chemotherapy and identify predictive markers for treatment response.
- To discuss the prognostic significance of genetic lesions in ODG.
Main Methods:
- Review of recent clinical trials and genetic studies on oligodendroglioma.
- Analysis of chemotherapy response rates in relation to tumor grade and genetic status.
- Correlation of genetic lesions (1p36, 19q13.3) with treatment outcomes and survival.
Main Results:
- ODG shows significant sensitivity to chemotherapy, with response rates of 60-65%.
- The presence of 1p36 and 19q13.3 deletions strongly correlates with favorable chemotherapy response and improved progression-free survival after radiation.
- Tumors lacking these deletions but possessing TP53 or glioblastoma-like genetic features may represent a distinct entity.
Conclusions:
- 1p36 and 19q13.3 deletions are important prognostic markers for selecting ODG patients for chemotherapy.
- Chemotherapy, including schedules beyond PCV, is effective for both low and high-grade ODG.
- Further research into novel chemotherapy regimens and molecular targets is crucial for improving outcomes in relapsed or refractory ODG.